Clinical updates, including trial initiations, enrollment status and data readouts and publications: Anaptysbio, Avadel, Axsome, BMS, Eli Lilly, Enlivex, Genentech, Humanigen, Innovent, Kamada, Krystal, Logicbio, Ovid, Pharming, Precigen, Rhovac, Seres.
Out of 922 biopharma financings so far in 2020, nearly a quarter of them – 211 – were done by companies working on a COVID-19 therapeutic or vaccine. More strikingly, however, the $27.8 billion raised by those pandemic-focused firms represents about 40% of the $71.8 billion total collected through the end of July. That amount is the highest BioWorld has ever tracked.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bayer, Biogen, Canbridge, Cytodyn, Eisai, Intellia, Kazia, PTC, Roche, Viiv.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Anavex, Catalyst, GSK, Jaguar, Neurorx, Organicell, Redhill, Relief, Tonix, Y-mabs.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adamis, Astrazeneca, Aveo, CSL, Daiichi, Galmed, Glaxosmithkline, Immatics, Iovance, Kyowa Kirin, Mirati, Oric, Seattle Genetics, Sab, Som, Veracyte.
With strong results in hand from the phase I stage of its phase I/II study testing a would-be COVID-19 subunit vaccine, Novavax Inc.’s president of R&D, Gregory Glenn, said “it’s possible we could go down in the dose” as work proceeds and get similar efficacy.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Axsome, Diurnal, Pharmacyte, Revive.
RSS
